US6967208 — Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Method of Use · Assigned to Bristol Myers Squibb Pharma Co · Expires 2026-11-21 · 1y remaining
What this patent protects
This patent protects lactam-containing compounds and their derivatives that inhibit factor Xa, a type of enzyme.
USPTO Abstract
The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Drugs covered by this patent
- Eliquis (apixaban) · Bristol-Myers Squibb
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4179 |
— | Eliquis |
U-4180 |
— | Eliquis |
U-1501 |
— | Eliquis |
U-1301 |
— | Eliquis |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.